share_log

SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Nirland Limited(2.0%),Stockton Limited(2.0%), etc.

SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Nirland Limited(2.0%),Stockton Limited(2.0%), etc.

SC 13G/A：超過5%持股股東披露文件(修正)-Nirland Limited(2.0%),Stockton Limited(2.0%)等
美股SEC公告 ·  2024/10/18 13:19

Moomoo AI 已提取核心訊息

On October 11, 2024, an amendment to Schedule 13G was filed with the United States Securities and Exchange Commission by Conduit Pharmaceuticals Inc., indicating a change in ownership by several related entities. The filing, known as Amendment No. 3, details the shared beneficial ownership of 2,000,000 shares of common stock by Nirland Limited, Stockton Limited, The Rowland Master Trust, and Dovet Limited, all of which are organized in Guernsey. These shares represent 2.0% of the class and are connected to a common stock warrant that became exercisable following a business combination. The entities have a joint filing agreement and may be deemed to share voting and dispositive power over the securities held by Nirland Limited. The filing clarifies that this should not be construed as an admission that the reporting persons are the beneficial owners of the reported securities for the purposes of Section 13 of the Securities Exchange Act of 1934.
On October 11, 2024, an amendment to Schedule 13G was filed with the United States Securities and Exchange Commission by Conduit Pharmaceuticals Inc., indicating a change in ownership by several related entities. The filing, known as Amendment No. 3, details the shared beneficial ownership of 2,000,000 shares of common stock by Nirland Limited, Stockton Limited, The Rowland Master Trust, and Dovet Limited, all of which are organized in Guernsey. These shares represent 2.0% of the class and are connected to a common stock warrant that became exercisable following a business combination. The entities have a joint filing agreement and may be deemed to share voting and dispositive power over the securities held by Nirland Limited. The filing clarifies that this should not be construed as an admission that the reporting persons are the beneficial owners of the reported securities for the purposes of Section 13 of the Securities Exchange Act of 1934.
2024年10月11日，Conduit Pharmaceuticals Inc.向美國證券交易委員會提交了修改後的13G表格，表明幾個相關實體的所有權發生了變化。這份被稱爲第3號修正案的申報詳細說明了尼蘭德有限公司、斯托克頓有限公司、羅蘭德控股信託以及多維特有限公司在根西組織的共同持有20萬股普通股權益。這些股票佔該類別的2.0%，與一項隨後進行的業務組合後變得可行使的普通股認股權證有關。這些實體有聯合申報協議，並可能被視爲與尼蘭德有限公司持有的證券共享投票和處分權。該申報澄清，不應被解釋爲報告人就證券交易法案第13條的目的而是報告證券的受益所有者。
2024年10月11日，Conduit Pharmaceuticals Inc.向美國證券交易委員會提交了修改後的13G表格，表明幾個相關實體的所有權發生了變化。這份被稱爲第3號修正案的申報詳細說明了尼蘭德有限公司、斯托克頓有限公司、羅蘭德控股信託以及多維特有限公司在根西組織的共同持有20萬股普通股權益。這些股票佔該類別的2.0%，與一項隨後進行的業務組合後變得可行使的普通股認股權證有關。這些實體有聯合申報協議，並可能被視爲與尼蘭德有限公司持有的證券共享投票和處分權。該申報澄清，不應被解釋爲報告人就證券交易法案第13條的目的而是報告證券的受益所有者。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    2seventy bio
    TSVT
    -- 4.950
    Syros Pharmaceuticals
    SYRS
    -- 0.1360
    Dogwood Therapeutics
    DWTX
    -- 11.130
    Camp4 Therapeutics
    CAMP
    -- 5.490
    Anebulo Pharmaceuticals
    ANEB
    -- 1.390
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    科技巨頭財報季如火如荼，英偉達壓軸會表現如何？
    週四， $亞馬遜 (AMZN.US)$ 該公司報告第四季度調整後每股收益爲1.86美元，高於1.50美元的預期，營業收入爲1877.9亿美元，高於1873.2亿美元的預期。公司預測下一季度營收將低於華爾街的預期，預計本季度最多爲1550亿美元，而分析師們希望達到1580亿美元。 展开
    亞馬遜收益預覽：通過猜測開盤價格獲得獎勵！